Premium
Proton MR spectroscopy in clinical routine
Author(s) -
Burtscher Isabella M.,
Holtås Stig
Publication year - 2001
Publication title -
journal of magnetic resonance imaging
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.563
H-Index - 160
eISSN - 1522-2586
pISSN - 1053-1807
DOI - 10.1002/jmri.1079
Subject(s) - proton magnetic resonance , in vivo magnetic resonance spectroscopy , nuclear magnetic resonance , myelin , in vivo , brain function , brain tissue , proton , nuclear magnetic resonance spectroscopy , magnetic resonance imaging , medicine , medical physics , nuclear medicine , neuroscience , biomedical engineering , biology , central nervous system , physics , radiology , microbiology and biotechnology , quantum mechanics
In vivo magnetic resonance spectroscopy (MRS) addresses metabolic pathways and their steady states in different tissue types. The brain has by tradition, and due to technical limitations in other organs, been one of the tissues most studied by MRS, and both 1 H‐ and 31 P‐MRS have been used. Although 31 P‐MRS is outstanding for the evaluation of sources of metabolic energy in the brain, 1 H‐MRS has become the major clinically applied method in neurospectroscopy, as it provides information on markers of neuronal function, myelin, cell membranes, and metabolic active compounds. Furthermore, MR sensitivity is much greater for protons than it is for phosphorus and 1 H‐MRS, therefore allowing better spatial resolution. This review focuses on neurospectroscopy and diagnostic insights into diverse neurological problems provided by 1 H‐MRS applied as a clinical tool. J. Magn. Reson. Imaging 2001;13:560–567. © 2001 Wiley‐Liss, Inc.